Premier Health Announces Name Change To CloudMD

Premier Health Group Inc (CSE: PHGI) announced this morning that the company will be changing its name to better reflect its current operations. As of February 24, the company will be known as CloudMD Software & Services Inc and trade under the ticker symbol “DOC” on the Canadian Securities Exchange.

The name change is intended to be more reflective of the firms core operations, which largely consists of its telemedicine offerings. The new name places a greater emphasis on the strategic focus of Premier Health to focus on its digital health and telemedicine based revenue.

In conjunction with the name change, a new website will be launched by CloudMD on Monday, February 24 to reflect the rebranding of the company.

We are excited to be announcing our name change to reflect the Company’s strategic focus on increasing our digital health and telemedicine based revenue. With the recent launch of our direct to consumer telemedicine app, CloudMD, we are focused on getting the over 5 million patients in BC access to the care they need, when they need it. Leveraging the latest developments in technologies like 5G, the days of waiting weeks for a doctor’s appointment or rushing to an emergency room during a viral outbreak like the coronavirus are quickly disappearing.

Dr. Essam Hamza, CEO of Premier Health

The announcement of the name change follows the launch of Premier Health’s direct-to-consumer app, CloudMD, which was launched earlier this month. Currently available to BC residents, the app enables consumers to obtain quality access to care via their mobile phone, desktop, or tablet. The application connections physicians with patients in minutes, and is directly billed to the provincial Medical Services Plan.

Premier Health last traded at $0.44 on the CSE.

FULL DISCLOSURE: Premier Health Group is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Premier Health Group on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.